Skip to main content

Table 4 Effects of hydroponically (HyL) and soil-grown (SoL) lettuce on pancreas, liver, kidney and brain biomarkers in tissue

From: In vitro and in vivo evaluations of antioxidative, anti-Alzheimer, antidiabetic and anticancer potentials of hydroponically and soil grown Lactuca sativa

Organ

Treatment

TBARS (nM/min/ mg tissue)

CAT (U/min)

SOD (U/mg protein)

GPOD (U/min)

GSH (mM/g tissue)

Pancreas

Normal control

32.6 ± 1.6cdef

5.8 ± 0.04cdef

2.9 ± 0.8ns

5.6 ± 0.7cdef

9.5 ± 0.6cdef

Diabetic control

41.2 ± 2.1acd

1.9 ± 0.02ach

1.5 ± 0.05ns

2.9 ± 0.07ah

5.2 ± 0.3h

Glibenclamide 10mg/kg

33.1 ± 1.3cdef

5.2 ± 0.05cdef

2.7 ± 0.02ns

5.0 ± 0.04cdef

8.9 ± 0.1cdef

HyL 200mg/kg

36.4 ± 2.5acdefh

4.8 ± 0.09cdef

2.5 ± 0.07ns

4.5 ± 0.8cde

8.1 ± 0.5cdefh

HyL 100mg/kg

37.3 ± 3.1adefh

3.5 ± 0.05aeh

1.9 ± 0.0ns

3.8 ± 0.6cdeh

7.2 ± 0.4adefh

HyL 50mg/kg

38.4 ± 2.1aefh

2.9 ± 0.08ah

1.6 ± 0.04 ns

3.2 ± 0.2aeh

6.5 ± 0.3ah

SoL 200mg/kg

38.1 ± 1.3aefh

2.8 ± 0.04ah

1.9 ± 0.06ns

2.1 ± 0.6ah

6.3 ± 0.8ah

SoL 100mg/kg

39.1 ± 3.3aefh

2.2 ± 0.06ah

1.5 ± 0.05ns

1.9 ± 0.7ah

5.5 ± 0.2ah

SoL 50mg/kg

40.9 ± 3.6acdh

1.8 ± 0.08ah

1.3 ± 0.04ns

1.5 ± 0.8ah

4.9 ± 0.6ah

Liver

Normal control

37.3 ± 3.2cdef

14.1 ± 1.1cdef

5.1 ± 0.03ns

5.2 ± 0.03ns

10.4 ± 0.5cdef

Diabetic control

55.1 ± 2.9ac

10.2 ± 1.2ah

3.2 ± 0.01ns

4.0 ± 0.03ns

5.8 ± 0.3ah

Glibenclamide 10mg/kg

39.8 ± 3.1cdefh

13.9 ± 1.0cdef

4.9 ± 0.02ns

4.9 ± 0.02ns

10.1 ± 0.2cdef

HyL 200mg/kg

45.9 ± 3.1acdefh

12.4 ± 1.0cde

4.1 ± 0.8ns

4.5 ± 0.06ns

9.6 ± 0.8cdef

HyL 100mg/kg

47.6 ± 4.1acdefh

11.3 ± 1.2ah

3.6 ± 0.6ns

4.1 ± 0.04ns

8.2 ± 0.4e

HyL 50mg/kg

50.8 ± 3.6aefh

10.5 ± 1.3ah

4.5 ± 0.4ns

3.8 ± 0.0ns

7.3 ± 0.9ah

SoL 200mg/kg

51.2 ± 4.8aefh

9.8 ± 1.8ah

3.9 ± 0.6ns

3.8 ± 0.08ns

6.8 ± 0.5ah

SoL 100mg/kg

52.6 ± 5.1ah

9.5 ± 1.4ah

3.2 ± 0.7ns

3.5 ± 0.01ns

6.1 ± 0.9ah

SoL 50mg/kg

54.8 ± 3.6ach

9.1 ± 1.3ah

2.9 ± 0.3ns

3.2 ± 0.03ns

5.3 ± 0.5ah

Kidney

Normal control

30.0 ± 3.4acdef

13.8 ± 0.7de

3.9 ± 0.5ns

4.5 ± 0.5f

8.0 ± 0.8cdef

Diabetic control

58.2 ± 4.5acd

11.0 ± 0.8ns

1.4 ± 0.05ns

1.2 ± 0.01ach

3.3 ± 0.6ah

Glibenclamide 10mg/kg

35.2 ± 3.6cdefh

13.3 ± 0.8de

3.5 ± 0.02ns

4.4 ± 0.01f

7.7 ± 0.04cdef

HyL 200mg/kg

40.3 ± 4.6acdefh

12.9 ± 0.9e

2.6 ± 0.6ns

3.9 ± 0.6ns

7.1 ± 0.6cdef

HyL 100mg/kg

45.3 ± 4.8adefh

12.2 ± 1.3e

1.9 ± 0.2ns

2.5 ± 0.5ns

6.2 ± 0.2ef

HyL 50mg/kg

51.6 ± 5.2acefh

11.8 ± 1.2ns

4.5 ± 0.1def

1.3 ± 0.6ah

5.1 ± 0.5h

SoL 200mg/kg

47.9 ± 2.5adefh

11.5 ± 1.1ns

2.0 ± 0.8ns

4.1 ± 0.8f

4.2 ± 0.02ah

SoL 100mg/kg

52.7 ± 4.6acefh

10.3 ± 1.5ah

1.5 ± 0.4ns

2.9 ± 0.4ns

3.5 ± 0.6ah

SoL 50mg/kg

57.4 ± 4.1acdh

9.2 ± 1.2ah

1.2 ± 0.2ns

1.9 ± 0.1ns

2.9 ± 0.4ah

Brain

Normal control

15.2 ± 2.1bcdeg

5.2 ± 0.4ns

1.3 ± 0.05ns

5.9 ± 0.01ns

4.8 ± 0.6deg

Alzheimer control

29.6 ± 3.1bch

3.8 ± 0.01ns

0.4 ± 0.02ns

3.5 ± 0.7ns

1.9 ± 0.8bh

Rivastigmine 10mg/kg

18.9 ± 3.4cdegh

4.3 ± 0.01ns

1.1 ± 0.07ns

5.6 ± 0.02ns

4.6 ± 0.3eg

HyL 200mg/kg

20.2 ± 3.1cdegh

4.0 ± 0.9ns

0.9 ± 0.02ns

5.0 ± 0.4ns

4.2 ± 0.4ns

HyL 100mg/kg

25.6 ± 4.3bdegh

3.8 ± 0.6ns

0.6 ± 0.01ns

4.4 ± 0.1ns

3.5 ± 0.6ns

HyL 50mg/kg

28.4 ± 4.6bch

4.7 ± 0.8ns

0.4 ± 0.02ns

3.8 ± 0.5ns

2.8 ± 0.2ns

SoL 200mg/kg

25.5 ± 2.9cbdegh

5.0 ± 1.3ns

0.5 ± 0.01ns

4.5 ± 0.03ns

2.7 ± 0.8ns

SoL 100mg/kg

28.9 ± 3.9dbch

5.3 ± 1.0ns

0.3 ± 0.03ns

4.0 ± 0.2ns

2.2 ± 0.3h

SoL 50mg/kg

30.3 ± 3.4bch

5.4 ± 1.2ns

0.1 ± 0.01ns

3.1 ± 0.3b

1.8 ± 0.5bh

  1. Values expressed as means (n = 7) ± SD with *p < 0.05 in comparison with Glibenclamide representing “a”, Rivastigmine representing “b”, SoL 200 mg/kg representing “c”, SoL 100 mg/kg representing “d”, SoL 50 mg/kg representing “e”, diabetic control representing “f”, Alzheimer’s control representing “g” and normal control representing “h” with all respective concentrations of HyL and controls. “ns” represent non significance